Anti-Human CD103 (ITGAE) (Clone CPTC-ITGAE-1) – Purified No Carrier Protein

Synthetic peptide VSYQLQTPEGQTDHPQPILDR

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0120A-5E10-H6/K2 activity is directed against human ITGAE peptide sequence VSYQLQTPEGQTDHPQPILDR.

CPTC-ITGAE-1

Integrins are a superfamily of transmembrane adhesion receptors that mediate cell-cell and cell- extracellular matrix adhesion, cell-pathogen interactions, cell cycle regulation, and cytoskeleton organization¹. Their functions affect proliferation, migration, cell survival, differentiation, and immune response. Integrins are heterodimers composed of paired α- and β-subunits. ITGAE (also known as αE or CD103) dimerizes exclusively to β7 to form integrin αEβ7, which functions in the selective recruitment of lymphocytes to epithelial barriers, anchoring of lymphocytes to epithelium, and activation of T cells at gut mucosal sites via its ligand E- cadherin, a junction protein expressed by epithelial cells². Integrin dysfunction is associated with cancer and immune diseases. In particular, αEβ7 is a target of immunotherapies for inflammatory bowel disease.

EB0120A-5E10-H6/K2 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from residues 787-807 of human ITGAE, VSYQLQTPEGQTDHPQPILDR³. EB0120A-5E10-H6/K2 does not detect ITGAE by immunohistochemistry, reverse phase protein array, or in cell lysates by Western blotting⁴. EB0120A-5E10-H6/K2 does detect recombinant ITGAE protein by Western blotting.

ITGAE is expressed on intraepithelial lymphocytes, a subclass of T lymphocytes located between mucosal epithelial cells and on some peripheral regulatory T cells, as well as on lamina propria T cells, some dendritic cells in gut mucosa, and mesenteric lymph nodes. ITGAE is also present in hairy cell leukemia and is used as a positive marker for identification of this cancer. ITGAE is also used as a biomarker to identify tissue-resident immune cells.

Integrin beta 7 (β7– ITGB7), E-cadherin

1 Akasaka H, Sato D, Shihoya W, et al. Biochem Biophys Res Commun. 721:150121. 2024.
2 Xu W, Bergsbaken T, Edelblum KL. Am J Physiol Cell Physiol. 323(4):C1161-C1167. 2022.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-ITGAE-1